RyotaroNakamuraMD

Hematology • Duarte, CA

Hematologic Oncology

Associate Professor

Join to view full profile

Dr. Nakamura is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nakamura's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-359-8111

Fax+1 626-301-8116

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
OtherClass of 1991

Certifications & Licensure

CA State Medical License 2002 - 2025
MD State Medical License 1998 - 2025

Clinical Trials

Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Start of enrollment: 2006 Nov 01
Completed
Phase 3
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma Start of enrollment: 2008 Jan 01
Completed
Phase 1
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Start of enrollment: 2010 Dec 01
Completed
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Start of enrollment: 2012 Oct 29
Completed
Phase 1
A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL Start of enrollment: 2013 Nov 25
Terminated
Phase 1, Phase 2
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
Completed
Phase 2
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL Start of enrollment: 2014 Nov 04
Terminated
Phase 1, Phase 2
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Start of enrollment: 2018 Dec 01
Withdrawn
Phase 2
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant Start of enrollment: 2018 Aug 20
Active, not recruiting
Phase 1
CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant Start of enrollment: 2019 Apr 18
Active, not recruiting
Phase 1
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation Start of enrollment: 2019 Nov 27
Active, not recruiting
Phase 2
MM CAR-T to Upgrade Response BMTCTN1902 Start of enrollment: 2022 Jan 05
Active, not recruiting
Phase 2
Roles: Contact
A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia Start of enrollment: 2024 Aug 01
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

499 citations
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
Stefan O. Ciurea, Mei-Jie Zhang, Andrea Bacigalupo, Asad Bashey, Frederick R. Appelbaum
Blood. 2015-08-20
33 citations
Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia.
Karamjeet S. Sandhu, Sanjeet Dadwal, Dongyun Yang, Matthew Mei, Joycelynne Palmer
Biology of Blood and Marrow Transplantation. 2020-12-01
84 citations
Comparison of Reduced-Intensity and Conventional Myeloablative Regimens for Allogeneic Transplantation in Non-Hodgkin’s Lymphoma
Roberto Rodriguez, Auayporn Nademanee, Nora Ruel, Eileen P. Smith, Amrita Krishnan
Biology of Blood and Marrow Transplantation. 2006-12-01

Abstracts/Posters

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients
Ryotaro Nakamura, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Large-Scale Manufacturing of CMV-CD19CAR T Cells and Characterization of Their Biologic and Immunologic Properties
Ryotaro Nakamura, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...
Ryotaro Nakamura, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizu...
Ryotaro Nakamura, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identif...
Ryotaro Nakamura, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Ver...
Ryotaro Nakamura, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Incidence and Risk Factors of De Novo Skin Cancer in a Contemporary Cohort of Hematopoietic Cell Transplantation Survivors
Ryotaro Nakamura, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Cytokine Gene Polymorphisms Are Associated with Disease Response to Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Q&A: Part Two: Paroxysmal Nocturnal Hemoglobinuria in Older PatientsJuly 8th, 2024
CD8 T Cells May Fight COVID-19 Infection in Hematological Cancer When B Cells, Antibodies WaneJune 11th, 2021
City of Hope Now Enrolling Patients for Phase 1 Type 1 Diabetes Investigational Vaccine TrialDecember 10th, 2020
Join now to see all